Alzheimer’s therapy breakthrough

On the 4th of June AFFiRiS, based in Vienna, Austria will hold a press conference to present final data of a clinical trial phase II of its proprietary Alzheimer's therapy. More than 300 patients were included in the international multi-centric clinical trial and significant effects have been observed.

Data will be presented by Dr Walter Schmidt, the company’s CEO and co-founder and Dr Frank Mattner, the CSO and co-founder.

The press conference will take place at the Vienna Marriott Hotel at 10.00 am CEST. There will be a live webcast of the event.

Based on the company's own patent positions, AFFiRiS develops tailor-made peptide vaccines (and more) for Alzheimer's disease, Atherosclerosis, Parkinson's disease, diabetes and several other conditions with urgent requirement for new treatments and attractive market volumes. Alzheimer's is the current lead indication. 

To find out more visit www.affiris.com

Recent Issues